Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Eton Pharmaceuticals, Inc.ETON · Nasdaq | 1 asset: 1 Ph 3 | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | None on record | $1.8B | $56MSep 2026 | Cash-flow positive | $9.9M |
Stoke Therapeutics, Inc.STOK · Nasdaq | 2 assets: 1 Ph 3, 1 other | ZorevunersenPhase 3 · Dravet SyndromeWeak signal | Mar 2027Zorevunersen · Phase 3 | $1.7B | $319MSep 2026 | ~6.1 qtrs | $191M |
Maze TherapeuticsMAZE · Nasdaq | 1 asset: 1 Ph 2 | MZE829Phase 2 · Chronic Kidney Disease | None on record | $1.7B | $391MSep 2026 | ~13.6 qtrs | $137M |
Vir BiotechnologyVIR · Nasdaq | 1 asset: 1 Ph 3 | Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis Delta | Dec 2026Tobevibart (VIR-3434) · Phase 3 | $1.6B | $463MSep 2026 | ~13.1 qtrs | $413M |
Sarepta TherapeuticsSRPT · Nasdaq | 3 assets: 2 Ph 2, 1 Ph 1 | SRP-1001Phase 1/2 · Facioscapulohumeral Muscular Dystrophy | 31 Dec 2026SRP-1003 · Phase 1/2 | $1.6B | $879MSep 2026 | Cash-flow positive | $653M |
Nurix Therapeutics, Inc.NRIX · | 2 assets: 1 Ph 3, 1 Ph 1 | bexobrutidegPhase 3 · Chronic Lymphocytic Leukemia | Jan 2027bexobrutideg · Phase 1 | $1.5B | $1.0BAug 2026 | Cash-flow positive | $334M |
Precigen, IncPGEN · | 3 assets: 1 approved, 1 Ph 2, 1 Ph 1 | PRGN-2009Phase 2 · HPV-Associated Oropharyngeal CancerWeak signal | 2 Dec 2027Zopapogene imadenovec · Approved | $1.5B | $46MSep 2026 | ~2.5 qtrs | ~$30M |
Kailera TherapeuticsKLRA · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 2 | ribupatidePhase 3 · ObesityReliable signal | Dec 2026Safiglipron (HRS-7535) · Phase 2 | $1.5B | $901MSep 2026 | ~11.7 qtrs | ~$284M |
MesoblastMESO · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | rexlemestrocel-LPhase 3 · Heart FailurePartial signal | Jul 2027rexlemestrocel-L · Phase 3 | $1.5B | $122MMar 2026 | ~29.8 qtrs | $35M |
Pacira BioSciences, Inc.PCRX · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $1.5B | $296MSep 2026 | Cash-flow positive | $123M |
AnaptysBioANAB · Nasdaq | 1 asset: 1 Ph 3 | ImsidolimabPhase 3 · PsoriasisPartial signal | None on record | $1.4B | $153MSep 2026 | Cash-flow positive | $122M |
Rapport Therapeutics, Inc.RAPP · Nasdaq | 1 asset: 1 Ph 3 | RAP-219Phase 3 · EpilepsyWeak signal | Jun 2027RAP-219 · Phase 1 | $1.4B | $395MSep 2026 | ~13.1 qtrs | $149M |
Nuvation BioNUVB · NYSE | 2 assets: 1 approved, 1 Ph 3 | safusidenibPhase 3 · Glioma | 2 Feb 2027Taletrectinib · Phase 1 | $1.3B | $663MSep 2026 | ~25.0 qtrs | $133M |
MannKind CorporationMNKD · Nasdaq | 3 assets: 3 approved | Approved assets only | Mar 2027Afrezza · Phase 2 | $1.3B | $97MSep 2026 | ~5.8 qtrs | $77M |
InnovivaINVA · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $1.3B | $581MSep 2026 | Cash-flow positive | $20M |
OCULAR THERAPEUTIX, INCOCUL · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | Axitinib intravitreal implant (OTX-TKI)Phase 3 · Age-Related Macular DegenerationPartial signal | 8 Jan 2027Axitinib intravitreal implant (OTX-TKI) · Phase 3 | $1.3B | $532MSep 2026 | ~8.4 qtrs | $246M |
uniQureQURE · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | AMT-260Phase 1/2 · Epilepsy | 30 Nov 2026AMT-260 · Phase 1/2 | $1.3B | $670MSep 2026 | ~13.9 qtrs | $133M |
OPKO HealthOPK · Nasdaq | 3 assets: 2 approved, 1 Ph 2 | OPK-88006Phase 1/2 · MASH / NASH | Oct 2027Extended-release calcifediol · Phase 2 | $1.3B | $403MSep 2026 | ~12.9 qtrs | $127M |
Alto NeuroscienceANRO · NYSE | 6 assets: 6 Ph 2 | ALTO-100Phase 2 · Major Depressive DisorderPartial signal | Dec 2026ALTO-300 · Phase 2 | $1.2B | $320MSep 2026 | ~16.2 qtrs | $73M |
Avalyn Pharma Inc.AVLN · Nasdaq | 1 asset: 1 Ph 2 | Pirfenidone (AP01)Phase 2 | Jun 2027Pirfenidone (AP01) · Phase 2 | $1.2B | $327MSep 2026 | ~13.2 qtrs | ~$95M |
Harrow, Inc.HROW · Nasdaq | 4 assets: 4 approved | Approved assets only | None on record | $1.2B | $75MSep 2026 | ~15.9 qtrs | $36M |
Savara Inc.SVRA · Nasdaq | 1 asset: 1 Ph 3 | molgramostimPhase 3 · Autoimmune Pulmonary Alveolar ProteinosisReliable signal | Jun 2027molgramostim · Phase 3 | $1.2B | $130MSep 2026 | ~4.0 qtrs | $91M |
Nektar TherapeuticsNKTR · Nasdaq | 2 assets: 1 Ph 3, 1 other | rezpegaldesleukinPhase 3 · Atopic DermatitisPartial signal | May 2028rezpegaldesleukin · Phase 3 | $1.2B | $614MSep 2026 | ~9.6 qtrs | $149M |
KardiganKARD · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | DanicamtivPhase 3 · Heart FailureWeak signal | Dec 2026Tonlamarsen · Phase 2 | $1.2B | $472MSep 2026 | ~8.9 qtrs | $189M |
LB PharmaceuticalsLBRX · Nasdaq | 1 asset: 1 Ph 3 | LB-102 (methylated amisulpride)Phase 3 · SchizophreniaReliable signal | None on record | $1.1B | $404MSep 2026 | ~11.3 qtrs | $119M |
Mineralys TherapeuticsMLYS · Nasdaq | 1 asset: 1 Ph 3 | LorundrostatPhase 3 · HypertensionReliable signal | None on record | $1.1B | $625MSep 2026 | ~16.3 qtrs | $293M |
GH ResearchGHRS · Nasdaq | 1 asset: 1 Ph 2 | Mebufotenin (5-MeO-DMT)Phase 2 · Major Depressive DisorderPartial signal | None on record | $1.1B | $246MDec 2025 | ~22.6 qtrs | $39M |
COMPASS PathwaysCMPS · Nasdaq | 1 asset: 1 Ph 3 | Psilocybin (COMP360)Phase 3 · Major Depressive DisorderReliable signal | Nov 2028Psilocybin (COMP360) · Phase 2/3 | $1.1B | $444MSep 2026 | ~10.1 qtrs | $109M |
Jade Biosciences, Inc.JBIO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | JADE101Phase 3 · IgA Nephropathy | May 2027JADE101 · Phase 1 | $1.1B | $476MSep 2026 | ~14.6 qtrs | $145M |
Vor BioVOR · Nasdaq | 1 asset: 1 Ph 3 | TelitaciceptPhase 3 · Rheumatoid ArthritisReliable signal | 31 Dec 2026Telitacicept · Phase 3 | $1.1B | $482MSep 2026 | ~16.2 qtrs | $97M |
Omeros CorporationOMER · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $1.1B | $132MJun 2026 | ~7.7 qtrs | $63M |
Inhibrx Biosciences, IncINBX · | 2 assets: 1 Ph 3, 1 Ph 2 | OrdastobartPhase 2/3 · Head and Neck Squamous Cell Carcinoma | 28 Feb 2027Ordastobart · Phase 2 | $1.0B | $199MSep 2026 | ~6.0 qtrs | $100M |
Seaport TherapeuticsSPTX · Nasdaq | 1 asset: 1 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 | $980M | $290MSep 2026 | ~13.7 qtrs | ~$90M |
| 2 assets: 2 Ph 2 | MRT-2359Phase 2 · Prostate Cancer | Dec 2026MRT-2359 · Phase 1/2 | $924M | $583MSep 2026 | ~14.1 qtrs | $179M | |
MoonLake ImmunotherapeuticsMLTX · Nasdaq | 1 asset: 1 Ph 3 | sonelokimabPhase 3 · Psoriatic ArthritisReliable signal | 4 Jan 2027sonelokimab · Phase 3 | $875M | $501MSep 2026 | ~8.2 qtrs | $230M |
Verastem, Inc.VSTM · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | GFH375Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027GFH375 · Phase 2 | $866M | $173MSep 2026 | ~12.3 qtrswith a later raise | $180M |
Corvus PharmaceuticalsCRVS · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | soquelitinibPhase 3 · Peripheral T-Cell LymphomaWeak signal | 30 Dec 2026soquelitinib · Phase 1 | $860M | $203MSep 2026 | ~18.0 qtrs | $55M |
| 3 assets: 3 approved | Approved assets only | None on record | $806M | $166MSep 2026 | Cash-flow positive | $7.0M | |
Rigel PharmaceuticalsRIGL · | 5 assets: 4 approved, 1 Ph 2 | R289Phase 1/2 · Myelodysplastic Syndromes | 4 Dec 2026Vepdegestrant · Phase 1 | $801M | $99MSep 2026 | Cash-flow positive | $28M |
ORIC PharmaceuticalsORIC · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RinzimetostatPhase 3 · Prostate Cancer | Dec 2026Enozertinib · Phase 1 | $793M | $265MJun 2026 | ~9.5 qtrs | $122M |
Ironwood PharmaceuticalsIRWD · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | apraglutidePhase 3 · Short Bowel Syndrome | None on record | $791M | $86MSep 2026 | Cash-flow positive | $95M |
ArdelyxARDX · Nasdaq | 2 assets: 2 approved | Approved assets only | 26 Feb 2027Tenapanor (Ibsrela) · Phase 3 | $784M | $285MSep 2026 | 10+ years | $94M |
Lexicon PharmaceuticalsLXRX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | PilavapadinPhase 2 · Diabetic Peripheral Neuropathic PainPartial signal | Jan 2027Sotagliflozin (Inpefa) · Phase 3 | $766M | $183MSep 2026 | ~14.9 qtrs | $58M |
SyndaxSNDX · | 2 assets: 2 approved | Approved assets only | 6 Jan 2027Axatilimab · Phase 1/2 | $764M | $427MSep 2026 | ~9.6 qtrs | $273M |
Climb Bio, Inc.CLYM · Nasdaq | 1 asset: 1 Ph 2 | budoprutugPhase 2 · Primary Membranous Nephropathy | Apr 2027budoprutug · Phase 1 | $756M | $206MSep 2026 | ~15.6 qtrs | $44M |
| 2 assets: 1 Ph 3, 1 Ph 1 | PalazestrantPhase 3 · HR+/HER2- Metastatic Breast CancerWeak signal | 30 May 2027OP-3136 · Phase 1 | $714M | $414MSep 2026 | ~9.3 qtrs | $218M | |
Attovia TherapeuticsATTO · Nasdaq | 1 asset: 1 Ph 1 | ATTO-1310Phase 1 · Atopic Dermatitis | 30 Aug 2028ATTO-1310 · Phase 2 | $709M | $396MSep 2026 | ~19.4 qtrs | ~$65M |
Nuvectis PharmaNVCT · Nasdaq | 1 asset: 1 Ph 1 | NXP900Phase 1 · Non-Small Cell Lung Cancer | Dec 2026NXP900 · Phase 1 | $698M | $141MSep 2026 | ~36.0 qtrs | $41M |
Kura Oncology, Inc.KURA · Nasdaq | 2 assets: 1 approved, 1 Ph 1 | DarlifarnibPhase 1 · Non-Small Cell Lung Cancer | Dec 2026Ziftomenib · Phase 1 | $674M | $492MSep 2026 | ~11.6 qtrs | $258M |
Annexon, Inc.ANNX · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 1 | VonaprumentPhase 3 · Age-Related Macular DegenerationPartial signal | 31 May 2027tanruprubart · Phase 3 | $667M | $214MSep 2026 | ~4.5 qtrs | $166M |
InventivaIVA · Nasdaq | 1 asset: 1 Ph 3 | LanifibranorPhase 3 · MASH / NASHPartial signal | None on record | $655M | $100MDec 2024 | ~9.1 qtrswith a later raise | $98M |
Geron CorporationGERN · Nasdaq | 1 asset: 1 approved | Approved assets only | Feb 2027Imetelstat · Phase 1 | $638M | $286MSep 2026 | ~12.7 qtrs | $63M |
Janux TherapeuticsJANX · Nasdaq | 1 asset: 1 Ph 1 | JANX007Phase 1 · Prostate Cancer | Jul 2027JANX007 · Phase 1 | $631M | $946MSep 2026 | 10+ years | $120M |
| 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | Velinotamig (GR1803)Phase 3 · Multiple MyelomaWeak signal | Dec 2026CLN-978 · Phase 1 | $585M | $290MSep 2026 | ~7.0 qtrs | $170M | |
AlumisALMS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 | $560M | $433MSep 2026 | ~5.4 qtrs | $330M |
Aclaris TherapeuticsACRS · Nasdaq | 4 assets: 3 Ph 2, 1 other | BosakitugPhase 2 · Atopic DermatitisWeak signal | Mar 2029Modzatinib · Phase 2 | $555M | $114MSep 2026 | ~6.5 qtrs | $66M |
Wave Life SciencesWVE · Nasdaq | 4 assets: 4 Ph 2 | WVE-003Phase 1/2 · Huntington's DiseaseWeak signal | Sep 2027WVE-006 · Phase 1/2 | $546M | $431MSep 2026 | ~8.3 qtrs | $205M |
ArriVent BioPharmaAVBP · Nasdaq | 1 asset: 1 Ph 3 | FurmonertinibPhase 3 · Non-Small Cell Lung Cancer | Dec 2026Furmonertinib · Phase 3 | $537M | $393MSep 2026 | ~10.3 qtrs | $151M |
Gyre TherapeuticsGYRE · Nasdaq | 1 asset: 1 other | F230Pulmonary Arterial Hypertension | None on record | $500M | $57MSep 2026 | ~9.9 qtrs | $17M |
Aquestive Therapeutics, Inc.AQST · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 other | Diazepam (Libervant)Phase 3 · EpilepsyWeak signal | None on record | $475M | $90MSep 2026 | ~9.1 qtrs | $16M |
Capricor TherapeuticsCAPR · Nasdaq | 1 asset: 1 Ph 3 | deramiocelPhase 3 · Duchenne Muscular Dystrophy | None on record | $467M | $199MSep 2026 | ~6.6 qtrs | $109M |
BlossomHill TherapeuticsBLSM · | 2 assets: 1 Ph 2, 1 Ph 1 | BH-30643Phase 1/2 · Non-Small Cell Lung Cancer | 31 Jan 2029BH-30643 · Phase 1/2 | $464M | $225MSep 2026 | ~13.3 qtrs | ~$70M |
DiaMedica TherapeuticsDMAC · Nasdaq | 1 asset: 1 Ph 3 | Rinvecalinase alfaPhase 2/3 · Acute Ischemic Stroke | Dec 2026Rinvecalinase alfa · Phase 2/3 | $463M | $35MSep 2026 | ~4.1 qtrs | $32M |
Assembly BiosciencesASMB · Nasdaq | 1 asset: 1 Ph 1 | ABI-5366Phase 1 · Genital Herpes | None on record | $458M | $314MSep 2026 | ~31.0 qtrs | $67M |
Arvinas Inc.ARVN · | 4 assets: 1 approved, 2 Ph 2, 1 Ph 1 | LuxdegalutamidePhase 2 · Metastatic Castration-Resistant Prostate Cancer | 3 Dec 2026Luxdegalutamide · Phase 2 | $443M | $559MSep 2026 | ~14.1 qtrs | $221M |
Cypherpunk Technologies Inc.CYPH · Nasdaq | 1 asset: 1 Ph 2 | SirexatamabPhase 2 · Colorectal Cancer | None on record | $440M | $7.6MJun 2026 | Ended Nov 2026 | $2.6M |
Helus PharmaHELP · Nasdaq | 1 asset: 1 Ph 3 | DeupsilocinPhase 3 · Major Depressive DisorderPartial signal | None on record | $427M | — | — | $39M |
Tectonic TherapeuticTECX · Nasdaq | 1 asset: 1 Ph 2 | Fc-relaxin fusion protein (TX45)Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | 24 Nov 2026Fc-relaxin fusion protein (TX45) · Phase 2 | $420M | $235MSep 2026 | ~13.6 qtrs | $73M |
Candel Therapeutics, Inc.CADL · Nasdaq | 1 asset: 1 Ph 3 | Aglatimagene BesadenovecPhase 3 · Non-Small Cell Lung Cancer | Feb 2027Aglatimagene Besadenovec · Phase 2 | $417M | $204MSep 2026 | ~11.8 qtrs | $56M |
Avalo Therapeutics, Inc.AVTX · Nasdaq | 2 assets: 2 Ph 2 | QuisovalimabPhase 2 · AsthmaPartial signal | None on record | $387M | $393MSep 2026 | ~24.8 qtrs | $66M |
Jasper Therapeutics, Inc.JSPR · Nasdaq | 1 asset: 1 Ph 2 | BriquilimabPhase 1/2 · Chronic Spontaneous UrticariaPartial signal | None on record | $383M | $7.7MJun 2026 | Ended Aug 2026 | $37M |
Opus Genetics, Inc.IRD · Nasdaq | 1 asset: 1 Ph 3 | OPGx-LCA5Phase 3 · Leber Congenital Amaurosis | 15 Jun 2028OPGx-LCA5 · Phase 1/2 | $379M | $89MSep 2026 | ~7.3 qtrs | $47M |
Puma BiotechnologyPBYI · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | AlisertibPhase 2 · Small Cell Lung Cancer | 30 Oct 2027Alisertib · Phase 2 | $373M | $109MSep 2026 | Cash-flow positive | $74M |
ARS Pharmaceuticals, Inc.SPRY · Nasdaq | 1 asset: 1 approved | Approved assets only | Apr 2027Epinephrine · Approved | $367M | $138MSep 2026 | ~3.0 qtrs | $31M |
CorMedixCRMD · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Taurolidine/heparin · Phase 3 | $351M | $356MSep 2026 | Cash-flow positive | $30M |
Adlai Nortye Biopharma Co., Ltd.ANL · Nasdaq | 1 asset: 1 Ph 2 | PalupiprantPhase 2 · Non-Small Cell Lung CancerWeak signal | None on record | $350M | $61MDec 2024 | Ended Mar 2026 | $45M |
Lyell Immunopharma, Inc.LYEL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | Rondecabtagene autoleucelPhase 3 · Large B-Cell Lymphoma | Jun 2028LYL273 · Phase 1/2 | $341M | $179MSep 2026 | ~5.1 qtrs | $170M |
Prelude TherapeuticsPRLD · Nasdaq | 1 asset: 1 Ph 2 | PRT3789Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record | $340M | $152MJun 2026 | ~6.1 qtrs | $108M |
Immunic, Inc.IMUX · Nasdaq | 2 assets: 1 Ph 3, 1 other | vidofludimus calciumPhase 3 · Multiple Sclerosis | Nov 2026vidofludimus calcium · Phase 3 | $328M | $132MSep 2026 | ~5.5 qtrs | $95M |
ProKidneyPROK · Nasdaq | 1 asset: 1 Ph 3 | RilparencelPhase 3 · Chronic Kidney DiseaseWeak signal | Dec 2029Rilparencel · Phase 3 | $314M | $81MSep 2026 | ~2.1 qtrs | $145M |
MapLight TherapeuticsMPLT · Nasdaq | 1 asset: 1 Ph 2 | Betovumeline/fesoterodine (ML-007C-MA)Phase 2 · Alzheimer's DiseasePartial signal | Dec 2027Betovumeline/fesoterodine (ML-007C-MA) · Phase 2 | $309M | $305MJun 2026 | ~7.0 qtrs | $199M |
Galectin Therapeutics Inc.GALT · Nasdaq | 1 asset: 1 Ph 3 | belapectinPhase 2/3 · MASH / NASHPartial signal | None on record | $301M | $13MJun 2026 | ~2.7 qtrs | $8.9M |
| 1 asset: 1 Ph 1 | HWK-007Phase 1 · Non-Small Cell Lung Cancer | Oct 2028HWK-007 · Phase 1 | $294M | $170MSep 2026 | ~9.2 qtrs | $67M | |
Agenus Inc.AGEN · | 2 assets: 1 Ph 3, 1 Ph 2 | BotensilimabPhase 3 · Colorectal Cancer | Sep 2027Balstilimab · Phase 2 | $290M | $87MSep 2026 | ~3.3 qtrs | $46M |
EvommuneEVMN · NYSE | 3 assets: 3 Ph 2 | EVO101Phase 2 · Atopic DermatitisPartial signal | Oct 2027EVO756 · Phase 2 | $284M | $170MSep 2026 | ~7.5 qtrs | $89M |
Emergent BioSolutionsEBS · NYSE | 3 assets: 3 approved | Approved assets only | None on record | $283M | $177MSep 2026 | Cash-flow positive | $41M |
Autolus Therapeutics plcAUTL · Nasdaq | 1 asset: 1 approved | Approved assets only | Sep 2027obecabtagene autoleucel · Phase 1 | $282M | $250MSep 2026 | ~5.7 qtrs | $116M |
Eikon TherapeuticsEIKN · Nasdaq | 1 asset: 1 Ph 3 | ResiquimodPhase 2/3 · Non-Small Cell Lung Cancer | Dec 2026Resiquimod · Phase 2 | $280M | $462MSep 2026 | ~8.2 qtrs | $269M |
Inhibikase TherapeuticsIKT · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | Imatinib mesylate prodrug (IkT-001Pro)Phase 3 · Pulmonary Arterial Hypertension | Jun 2029Imatinib mesylate prodrug (IkT-001Pro) · Phase 3 | $277M | $193MSep 2026 | ~15.7 qtrs | $46M |
C4 Therapeutics, Inc.CCCC · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | CemsidomidePhase 2 · Multiple Myeloma | Jun 2027CFT8919 · Phase 1 | $274M | $209MSep 2026 | ~10.5 qtrs | $99M |
AltimmuneALT · Nasdaq | 1 asset: 1 Ph 3 | pemvidutidePhase 3 · MASH / NASHReliable signal | 30 Sep 2027pemvidutide · Phase 2 | $270M | $265MSep 2026 | ~10.4 qtrs | $80M |
Q32 BioQTTB · Nasdaq | 1 asset: 1 Ph 2 | BempikibartPhase 2 · Atopic DermatitisPartial signal | None on record | $255M | $290MSep 2026 | 10+ years | $16M |
Protalix BioTherapeutics, Inc.PLX · NYSE American | 2 assets: 1 approved, 1 Ph 2 | PRX-115Phase 2 · Severe Refractory Gout | Oct 2027pegunigalsidase alfa · Phase 2/3 | $255M | $22MSep 2026 | Cash-flow positive | $22M |
Allogene Therapeutics, Inc.ALLO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | cemacabtagene ansegedleucelPhase 2 · Large B-Cell Lymphoma | Dec 2027cemacabtagene ansegedleucel · Phase 2 | $240M | $303MSep 2026 | ~11.2 qtrs | $133M |
Amarin CorporationAMRN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $236M | $323MSep 2026 | Cash-flow positive | $19M |
Lexeo TherapeuticsLXEO · Nasdaq | 1 asset: 1 Ph 2 | LX1001Phase 1/2 · Alzheimer's DiseaseWeak signal | Nov 2028LX1001 · Phase 1 | $232M | $215MJun 2026 | ~9.7 qtrs | $67M |
Vanda PharmaceuticalsVNDA · Nasdaq | 6 assets: 4 approved, 2 Ph 3 | ImsidolimabPhase 3 · PsoriasisPartial signal | 1 Dec 2026tradipitant · Phase 3 | $227M | $141MSep 2026 | ~4.6 qtrs | $122M |
Faeth Therapeutics, Inc.FTH · Nasdaq | 4 assets: 3 Ph 2, 1 other | SerabelisibPhase 2 · Endometrial CancerWeak signal | Sep 2028Serabelisib · Phase 2 | $225M | $175MSep 2026 | ~16.2 qtrs | — |
AC ImmuneACIU · Nasdaq | 3 assets: 3 Ph 2 | ACI-35.030Phase 2 · Alzheimer's DiseasePartial signal | 22 Dec 2026ACI-35.030 · Phase 2 | $214M | $115MDec 2025 | ~5.5 qtrs | $68M |
Palisade BioPALI · Nasdaq | 1 asset: 1 Ph 2 | PALI-2108Phase 2 · Ulcerative ColitisWeak signal | Oct 2027PALI-2108 · Phase 2 | $205M | $114MSep 2026 | ~18.3 qtrs | $31M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.